Cognitive Screening in Lung Cancer Patients

Recruiting now

Conditions studied: Lung Disease, NSCLC (Non-small Cell Lung Cancer), SCLC

In brief

This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC. The primary endpoint measure will be the presence of cognitive impairment during the first year after enrollment through the administration of a comprehensive neuropsychological assessment.

Key facts

Study ID

NCT06727370

Run by

European Institute of Oncology

People needed

200

Starts

2024-01-10

Expected to finish

2025-12-31

Last updated by the study team

2024-12-10

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Small-cell and non-small-cell lung cancer (stage I, II, III, IV)
• Age ≥ 18 years
• Patients able to speak and read the local language(s) fluently
• Acceptance and signature of informed consent

You may not qualify if…

• Age ≥ 70
• Presence of brain metastases
• Patients with concomitant neurological or psychiatric disorders.
• Patients undergoing brain radiotherapy
• Previous diagnosis of lung cancer

Where it is running

• Istituto Europeo di Oncologia — Milan, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.